Literature DB >> 19326985

Use of morning serum cortisol level after transsphenoidal resection of pituitary adenoma to predict the need for long-term glucocorticoid supplementation.

Nicholas F Marko1, Vivek A Gonugunta, Amir H Hamrahian, Ali Usmani, Marc R Mayberg, Robert J Weil.   

Abstract

OBJECT: Accurate assessment of the hypothalamic-pituitary-adrenal (HPA) axis is critical for appropriate management of the disease in patients with pituitary adenoma after transsphenoidal resection. The authors examine the role of the morning total serum cortisol level in the early postoperative period as a predictor of long-term HPA function.
METHODS: Morning total serum cortisol was measured in 83 patients on postoperative Day 1 (or Day 2 if the patient received glucocorticoids during surgery) after transsphenoidal surgery for pituitary adenoma. These results were compared with those of definitive assays of HPA function performed at 1-3 months postoperatively, including cortrosyn/synacthen stimulation test (CST), insulin tolerance test (ITT), and metyrapone test (MTT). The ability of the early-postoperative morning cortisol level to predict HPA function was determined using standard confusion matrix calculations and receiver-operator control curve analysis.
RESULTS: The authors found that an early postoperative morning total cortisol level>or=15 microg/dl is a sensitive and accurate predictor of normal HPA function in the postoperative period (sensitivity 80.5%, specificity 66.7%, positive predictive value 96.9%).
CONCLUSIONS: A morning total cortisol level>or=15 microg/dl in the early postoperative period after transsphenoidal surgery for pituitary adenomas is a good predictor of normal HPA function. This test has good sensitivity and accuracy and correlates well with the results of additional, definitive assays of HPA function (CST, ITT, and MTT) performed at 1-3 months postoperatively. Accordingly, it is the authors' practice to avoid exogenous perioperative glucocorticoid supplementation in patients with normal preoperative HPA function and postoperative morning total cortisol levels>or=15 microg/dl 1-2 days after transsphenoidal pituitary adenomectomy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19326985     DOI: 10.3171/2008.12.JNS081265

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  13 in total

1.  Immediate postoperative cortisol levels accurately predict postoperative hypothalamic-pituitary-adrenal axis function after transsphenoidal surgery for pituitary tumors.

Authors:  Nicholas F Marko; Amir H Hamrahian; Robert J Weil
Journal:  Pituitary       Date:  2010-09       Impact factor: 4.107

2.  OUTCOME OF IMPLEMENTATION OF A MULTIDISCIPLINARY TEAM APPROACH TO THE CARE OF PATIENTS AFTER TRANSSPHENOIDAL SURGERY.

Authors:  Arthur S Carminucci; John C Ausiello; Gabrielle Page-Wilson; Michelle Lee; Laura Good; Jeffrey N Bruce; Pamela U Freda
Journal:  Endocr Pract       Date:  2015-10-05       Impact factor: 3.443

3.  Perioperative Outcomes of a Hydrocortisone Protocol after Endonasal Surgery for Pituitary Adenoma Resection.

Authors:  Tyler D Alexander; Sarah Collopy; Siyuan Yu; Michael Karsy; Chandala Chitguppi; Christopher J Farrell; James J Evans
Journal:  J Neurol Surg B Skull Base       Date:  2021-09-27

4.  The postoperative cortisol stress response following transsphenoidal pituitary surgery: a potential screening method for assessing preserved pituitary function.

Authors:  Gabriel Zada; Amir Tirosh; Abel P Huang; Edward R Laws; Whitney W Woodmansee
Journal:  Pituitary       Date:  2013-09       Impact factor: 4.107

5.  Perioperative management of patients undergoing transsphenoidal pituitary surgery.

Authors:  Gabriel Zada; Whitney W Woodmansee; Sherry Iuliano; Edward R Laws
Journal:  Asian J Neurosurg       Date:  2010-01

6.  Safety and cost effectiveness of early discharge following microscopic trans-sphenoidal resection of pituitary lesions.

Authors:  Jonathan A Forbes; Jani Wilkerson; Lola Chambless; Sheila D Shay; Clay M Elswick; Parker W Abblitt; Owoicho Adogwa; Paul Russell; Kyle D Weaver; George S Allen; Andrea L Utz
Journal:  Surg Neurol Int       Date:  2011-05-28

Review 7.  Is peri-operative steroid replacement therapy necessary for the pituitary adenomas treated with surgery? A systematic review and meta analysis.

Authors:  Mamatemin Tohti; Junyang Li; Yuan Zhou; Yuebing Hu; Zhuang Yu; Chiyuan Ma
Journal:  PLoS One       Date:  2015-03-16       Impact factor: 3.240

8.  Recovery Room Cortisol Predicts Long-Term Glucocorticoid Need After Transsphenoidal Surgery for Pituitary Tumors.

Authors:  Amro Qaddoura; Tenzin N Shalung; Michael P Meier; Jeannette Goguen; Rowan Jing; Stanley Zhang; Kalman Kovacs; Michael D Cusimano
Journal:  Neurosurgery       Date:  2019-03-01       Impact factor: 4.654

9.  Selective use of peri-operative steroids in pituitary tumor surgery: escape from dogma.

Authors:  Jacqueline Regan; Joseph Watson
Journal:  Front Endocrinol (Lausanne)       Date:  2013-03-18       Impact factor: 5.555

10.  Lower-dose perioperative steroid protocol during endoscopic endonasal pituitary adenoma resection.

Authors:  Nathan C Pecoraro; Daniel M Heiferman; Brendan Martin; Daphne Li; Stephen J Johans; Chirag R Patel; Anand V Germanwala
Journal:  Surg Neurol Int       Date:  2019-04-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.